Last updated: 2026-10-17 11:17:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
CareDx, Inc. (CDNA) operates in the SERVICES-MEDICAL LABORATORIES sector and is listed on NASDAQ. The stock is currently priced at $64.04, with a market capitalization of $3.45B and a P/E ratio of 31.07. Over the past 52 weeks, its price has ranged from $14.03 to $72.51. This page covers its latest market performance, valuation, price trends and company information.
$3.45B | |
$66.34 | |
$99.83 | |
$0.76 | |
$66.68 | |
1.23M | |
1.27M | |
31.07 | |
$72.51 | |
$14.03 | |
-- | |
-- |
CareDx, Inc. (CDNA) last closed at $66.68 as of 2026-10-16 23:57:00, unchanged from the previous close of $66.68.
During the latest regular trading session, CDNA traded between $0.76 and $99.83, with a volume of 1.23M shares. The closing price was near the upper end and near the upper end of its 52-week range.
Over the past seven days, CareDx, Inc. (CDNA) moved from $62.21 to $64.04, representing a gain of 2.95% ($1.83).
The stock traded between $61.19 and $68.17 during the period. The latest price is near the middle of the 7-day range, indicating moderate upward.
The average daily volume was 1.27 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 85.5%
CDNA is currently trading at $64.04, placing it 85.5% of the way from its 52-week low of $14.03 to its 52-week high of $72.51. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
| Industry | SERVICES-MEDICAL LABORATORIES |
| Employees | 765 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of CareDx, Inc. (CDNA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.